Zoetis Forecasts 9.3% Earnings Growth, Posts 6.2% Earnings Surprise
Zoetis expects 9.3% long-term earnings growth and delivered a 6.2% trailing four-quarter earnings surprise, earning a #2 earnings rank. The company, spun off from Pfizer, leads the animal health market across seven product categories and eight core species spanning livestock and companion animals.
1. Company Profile
Zoetis was created when Pfizer spun off its animal health unit and now offers products in seven major categories—including vaccines, parasiticides and diagnostics—serving eight core species: cattle, swine, poultry, fish, sheep, dogs, cats and horses.
2. Recent Financial Performance
Over the past four quarters, Zoetis delivered a 6.2% cumulative earnings surprise and holds a #2 earnings rank based on efficiency metrics, reflecting consistent profit delivery above analysts’ expectations.
3. Growth Outlook
Analysts project Zoetis to achieve 9.3% average annual earnings growth over the long term, driven by ongoing demand for both livestock and companion animal health solutions and expansion into emerging markets.